Latest Articles

The article highlights how large-scale and longitudinal studies, wearables and national data initiatives are advancing multiomics research to improve disease prediction and prevention.

This article explores how mass spectrometry is advancing research across biomedicine, environmental science and beyond by enabling precise molecular analysis.

This article explores how immune biomarkers can predict disease risk, guide treatment choices and overcome challenges to advance personalized medicine.

A Q&A with Dr. Corentin J. Gosling, lead author of an umbrella review, explores the evidence behind complementary and alternative autism therapies. Covering 200 trials and 10,000 participants, the review found no strong proof of benefit.

We spoke with Dr. Niranjan Bose, managing director (Health & Life Sciences Strategy) at Gates Ventures, about a new $1M prize to advance dementia research using artificial intelligence.

For many cancers, surgical resection is the primary treatment option. However, traditional tissue analysis is slow and error-prone; point-of-care MS tools like the MasSpec Pen could improve cancer detection.

Dr. Jennifer Mann, associate director of Science at UK Biocentre, explains why a blind spot in current direct-to-consumer genetic testing practices requires closer analysis and change.

We spoke with Dr. Niranjan Bose, managing director, Health & Life Sciences Strategy, Gates Ventures, about how proteomics-based biomarkers and international partnerships are changing the future of neurodegenerative disease research.

This article explores how mass spectrometry and emerging analytical techniques are helping researchers decode the aging proteome at multiple scales – from plasma to specific tissues to individual organelles.

Researchers are investigating blood-based biomarkers like pTau217 for Alzheimer’s detection, offering a less invasive alternative to traditional methods. However, challenges remain due to the interference of proteins from other organs.